WideMed sleep monitor granted CE Mark

WideMed will expand its collaboration with GE Healthcare, which will market the Morpheus Hx software in Europe.

WideMed Ltd. (TASE:WDMD) has obtained EU CE Mark for its Morpheus Ox and Morpheus Hx cardio-sleep information systems, which will allow the company to market the products in Europe. Following the CE Mark certification, WideMed will expand its collaboration with GE Healthcare, which will market the Morpheus Hx in Europe.

WideMed cites a study by Frost and Sullivan, which estimates the European sleep industry market at $10 billion, and that 20 million Europeans suffer from chronic sleep disorders.

The Morpheus Hx includes software based on algorithms that can monitor sleep derived from data from standard sleep monitors manufactured by GE Healthcare. GE Healthcare has over $17 billion in annual turnover. The Morpheus Ox system uses a signal oxymeter to analyze sleep measures.

WideMed expects to launch sales of the Morpheus Ox in Europe in early 2011, provided that the company's suppliers meet delivery schedules.

WideMed's investors include Guidant Corporation, Platinum Neurone Ventures and Ascend Technology Ventures LP. The company's share price rose 16.2% by mid-afternoon to NIS 1.07, giving a market cap of NIS 17 million.

Published by Globes [online], Israel business news - www.globes-online.com - on September 7, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס